glp-1 and mcas Drugs: For Multiple Chronic Conditions GLP-1 Orals and Multi-Agonists: Advancing

Working together with Germano Marri, an Italian research fellow, Marks and Samols began exploring the role glucagon played in activating insulin

Purpose-built for physicians Phentermine may help certain patients lose more weight after discontinuing GLP-1s Key takeaways: Patients on phentermine who gained weight on a GLP-1 had a median 3% weight loss the year after GLP-1 discontinuation

Depression often results in reduced motivation and energy levels, leading to decreased participation in physical activities and exercise [39]

While many studies have shown that dual agonists (GLP-1R/GIPR agonists) and tri-agonists (GLP-1R/GIPR/GCGR agonists) improve glycemia and body weight in amounts unprecedented by the single agents (Nauck & D'Alessio 2022), only a few have investigated their role in cardiovascular outcomes

Tirzepatide, for instance, stands out by targeting not only the GLP-1 receptor but also the glucose-dependent insulinotropic polypeptide (GIP) receptor, offering a dual mechanism of action